

8 August 2022

## **Incidence and Treatment of Diffuse Large B Cell Lymphoma (DLBCL)**

I am researching the incidence and treatment of Diffuse Large B Cell Lymphoma (DLBCL). Could you please answer the following questions?

- 1. Does your Trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which Trust do you refer DLBCL patients to?**

Belfast Trust can confirm that we do treat patients with Diffuse Large B Cell Lymphoma (DLBCL).

- 2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?**

From January to June 2022, Belfast Trust had 32 new diagnoses of DLBCL that would have received treatment. However as this covers a recent time period the data is not validated and so may not be fully representative of patient numbers.

- 3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **Other immuno-chemotherapy**
- **Other chemotherapy**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only**
- **Tisagenlecleucel**
- **Axicabtagene ciloleucel**
- **Lisocabtagene maraleucel**

This information is not readily available and would require a manual search of data, which would take more than 18 hours.

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

8 August 2022

**4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other Trusts for:**

- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtegene maraleucel)**

Since February 2022, 5 patients have been referred from Belfast Trust to another Trust for CAR-T.

**5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?**

Belfast Trust has one active trial – Stellar. As yet, no patients have been recruited. Five further trials are in the adoption phase.